Noto Hiroshi, Tsujimoto Tetsuro, Noda Mitsuhiko
Department of Diabetes and Metabolic Medicine, Center Hospital ; Department of Diabetes Research, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
J Diabetes Investig. 2012 Feb 20;3(1):24-33. doi: 10.1111/j.2040-1124.2011.00183.x.
Aims/Introduction: Emerging evidence from observational studies suggests that diabetes mellitus affects the cancer risk. However, whether there are differences in the magnitude of the influence of diabetes among ethnic groups is unknown.
We searched MEDLINE and the Cochrane Library for pertinent articles that had been published as of 4 April 2011, and included them in a meta-analysis of the risk of all-cancer mortality and incidence in diabetic subjects.
A total of 33 studies were included in the meta-analysis, and they provided 156,132 diabetic subjects for the mortality analysis and 993,884 for the incidence analysis. Cancer mortality was approximately 3%, and cancer incidence was approximately 8%. The pooled adjusted risk ratio (RR) of all-cancer mortality was significantly higher than for non-diabetic people (RR 1.32 [CI 1.20-1.45] for Asians; RR 1.16 [CI 1.01-1.34] for non-Asians). Diabetes was also associated with an increased RR of incidence across all cancer types (RR 1.23 [CI 1.09-1.39] for Asians; RR 1.15 [CI 0.94-1.43] for non-Asians). The RR of incident cancer for Asian men was significantly higher than for non-Asian men (P = 0.021).
Diabetes is associated with a higher risk for incident cancer in Asian men than in non-Asian men. In light of the exploding global epidemic of diabetes, particularly in Asia, a modest increase in the cancer risk will translate into a substantial socioeconomic burden. Our current findings underscore the need for clinical attention and better-designed studies of the complex interactions between diabetes and cancer. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00183.x, 2012).
目的/引言:观察性研究的新证据表明糖尿病会影响癌症风险。然而,不同种族群体中糖尿病影响程度是否存在差异尚不清楚。
我们检索了截至2011年4月4日发表在MEDLINE和Cochrane图书馆的相关文章,并将其纳入糖尿病患者全癌死亡率和发病率风险的荟萃分析。
荟萃分析共纳入33项研究,其中156,132名糖尿病患者用于死亡率分析,993,884名用于发病率分析。癌症死亡率约为3%,癌症发病率约为8%。所有癌症死亡率的合并调整风险比(RR)显著高于非糖尿病患者(亚洲人为RR 1.32 [CI 1.20 - 1.45];非亚洲人为RR 1.16 [CI 1.01 - 1.34])。糖尿病还与所有癌症类型的发病率RR增加相关(亚洲人为RR 1.23 [CI 1.09 - 1.39];非亚洲人为RR 1.15 [CI 0.94 - 1.43])。亚洲男性的癌症发病RR显著高于非亚洲男性(P = 0.021)。
与非亚洲男性相比,亚洲男性糖尿病患者患癌症的风险更高。鉴于全球糖尿病疫情的爆发,尤其是在亚洲,癌症风险的适度增加将转化为巨大的社会经济负担。我们目前的研究结果强调了临床关注以及对糖尿病与癌症之间复杂相互作用进行更精心设计研究的必要性。(《糖尿病研究杂志》,doi: 10.1111/j.2040 - 1124.2011.00183.x,2012年)